Search Results - "Karras, N.A."

Discerning Post HSCT Immune Response to the Influenza Vaccine and Methods to Improve Vaccine Efficacy by Karras, N.A, Verneris, M.R, DeFor, T.E, Sessions, W.M, Xu, X, Klimov, A

Get full text

Fludarabine-exposure predicts disease control following CD19-specific car t cell (tisagenlecleucel); a report from pediatric real-world car consortium by Curran, K.J., Fabrizio, V.A., Mauguen, A., Boelens, J.J., Baggott, C., Prabhu, S., Placenta, H., Phillips, C.L., Rossoff, J., Stefanski, H., Talano, J., Moskop, A., Margossian, S.P., Verneris, M.R., Myers, G., Karras, N.A., Brown, P.A., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A., Wilcox, R., Rabik, C.A., Chinnabhandar, V., Kunicki, M., Goksenin, A., Mackall, C., Laetsch, T.W., Schultz, L.M.

Get full text

A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD) by Gossai, N, Verneris, M R, Karras, N A, Gorman, M F, Patel, N J, Burke, M J

“…In patients with relapsed ALL, minimal residual disease (MRD) identified prior to allogeneic hematopoietic cell transplantation (HCT) is a strong predictor of…”
Get full text